超短波治疗慢性鼻窦炎伴鼻息肉:一项随机双盲假对照试验方案
本研究为单中心、双盲、假对照随机试验,计划纳入150例慢性鼻窦炎伴鼻息肉患者,随机接受活性超短波治疗(50 mA,27.12 MHz)或假治疗,每日20分钟、持续2周,并联合标准药物治疗。主要结局为SNOT-22评分从基线至12个月随访的变化,采用线性混合效应模型分析。
要点
- 超短波治疗为无创方式,声称有抗炎作用,但用于慢性鼻窦炎伴鼻息肉尚缺乏有力证据。
- 试验随机分配150例患者,活性治疗参数为50 mA、27.12 MHz,每日20分钟,持续2周。
- 主要结局为SNOT-22评分从基线至12个月随访的变化。
核心结论
- 本试验旨在填补超短波治疗慢性鼻窦炎伴鼻息肉疗效的关键证据空白。
- 若有效,超短波治疗可能作为无创辅助手段,有望减少糖皮质激素、手术和生物制剂的使用负担,并改善患者长期结局。
- 研究结果将为临床指南提供关键证据并指导未来研究。
研究设计与样本
- 单中心、双盲、假对照随机试验,计划随机分配150例慢性鼻窦炎伴鼻息肉患者。
- 干预组接受活性超短波治疗(50 mA,27.12 MHz),对照组接受假治疗,每日20分钟、持续2周,同时联合标准药物治疗。
- 主要结局为SNOT-22评分从基线至12个月随访的变化,采用线性混合效应模型分析,并进行敏感性分析处理缺失数据。
- 关键次要结局包括12个月随访时Lund-Kennedy内镜评分的变化。
- 试验注册于中国临床试验注册中心(ChiCTR2400092411),注册日期为2024年11月16日。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by persistent sinonasal inflammation and substantially impairs quality of life. Current treatments, including corticosteroids, surgery, and biologics, are limited by side effects and high recurrence rates. Ultrashort wave (USW) therapy, a non-invasive modality with purported anti-inflammatory effects, lacks robust evidence for its efficacy in CRSwNP. METHODS: This single-center, double-blind, sham-controlled trial will randomize 150 patients with CRSwNP to receive either active USW therapy (50 mA, 27.12 MHz) or sham treatment for 20 min daily over 2 weeks, alongside standard medical care. The sole primary outcome is the change in the 22-item Sino-Nasal Outcome Test (SNOT-22) score from baseline to the 12-month follow-up. Key secondary outcomes include the change in the Lund-Kennedy endoscopic score at the 12-month follow-up. The primary outcome will be analyzed using a linear mixed-effects model, and sensitivity analyses will be conducted to handle missing data. DISCUSSION: This trial aims to address a critical evidence gap regarding the efficacy of USW therapy for CRSwNP. If effective, USW therapy could offer a non-invasive adjunct, potentially reducing the burden of corticosteroids, surgery, and biologics while improving long-term patient outcomes. The findings will provide crucial evidence to inform clinical guidelines and direct future research. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2400092411). Registered on November 16, 2024.
引用
- Kong L, Zhang J, Zhu C, et al. Ultrashort wave therapy for chronic rhinosinusitis with nasal polyps: protocol for a randomized, double-blind, sham-controlled trial. Trials. 2025. PMID: 41057971. doi:10.1186/s13063-025-09167-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。